Obstetric outcomes following vitrification of in vitro and in vivo matured oocytes

Chian, Ri‐Cheng; Huang, Jacky; Gilbert, Lucy; Son, Weon‐Young; Holzer, Hananel; Cui, S.; Buckett, William; Tulandi, Togas; Tan, Seang Lin

doi:10.1016/j.fertnstert.2008.04.014

Cited by 193 publications

(139 citation statements)

References 49 publications

Supporting

Mentioning

127

Contrasting

Unclassified

Order By: Relevance

“…Higher IVM rate and lower incidence of aneuploidy in the group received amifostine prior to CP, indicated using IVM of oocytes is possible following utilization of protective drugs prior to chemotherapy. IVM has been listed as one of options to improve fertility preservation in cancer patients [25]. Cryopreservation of embryos has been recommended for fertility preservation before chemotherapy for breast cancer.…”

Section: Discussionmentioning

confidence: 99%

“…Ovarian tissue transplantation has been one of techniques for fertility preservation. However the risk of reintroducing cancer from stored ovarian tissue must be always considered [25]. Therefore IVM following chemotherapy and application of protective drugs such as amifostine is maybe a promising technique for fertility preservation in hormone sensitive disease such as endometrial [38] and ovarian cancers [39].…”

Section: Discussionmentioning

confidence: 99%

“…In vitro maturation (IVM) is a promising technique for treatment of human infertility. It can be used as alternative of oocyte recovery using gonadotropins for ovarian stimulation [25]. Furthermore, this technique is maybe a useful tool for evaluation of chromosome abnormalities in female gamete because with application of IVM female gamete is easily available in each stage to evaluate chromosome abnormalities.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

The influence of amifostine administration prior to cyclophosphamide on in vitro maturation of mouse oocytes

Golkar‐Narenji

Barekati

Eimani

et al. 2013

J Assist Reprod Genet

View full text Add to dashboard Cite

Purpose The protective effect of amifostine against cyclophosphamide (CP) was evaluated on mouse oocytes. Materials and methods Female mice were divided into four groups as follows: group1: cyclophosphamide (CP) (75 mg/kg, i.p) injection, group2: amifostine (250 mg/kg, i.p) injection, group3: amifostine (250 mg/kg, i.p) administered prior to CP (75 mg/kg, i.p) injection, Control group with injection of saline. About 21 days after injection, in vitro maturation (IVM) of oocytes was recorded. Furthermore the percentage of aneuploid oocytes was determined. Results In the CP group IVM rate was significantly decreased and aneploidy rate was significantly increased when compared to other groups (p<0.05). With the administration of Amifostine prior to CP injection IVM rate was increased and aneploidy rate was decreased. Discussion Depletion in IVM rate with administration of CP is due its adverse effects on oocyte quality. Amifostine administration prior to CP injection appears to modulate deleterious effects of CP on oocytes.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The influence of amifostine administration prior to cyclophosphamide on in vitro maturation of mouse oocytes

Golkar‐Narenji

Barekati

Eimani

et al. 2013

J Assist Reprod Genet

View full text Add to dashboard Cite

show abstract

“…Caution must therefore be exercised in extrapolating the data for both efficiency and safety to the young cancer patient population 46 . Variations on ivm techniques applied to cancer patients (for example, with respect to the degree of ovarian stimulation) make outcomes and success rates even more challenging to elucidate.…”

Section: Ivmmentioning

confidence: 99%

Oncofertility in Canada: cryopreservation and alternative options for future parenthood

Ronn¹,

Holzer²

2013

Curr. Oncol.

View full text Add to dashboard Cite

“…2. These trees expand upon other excellent decision-making resources that provide roadmaps for navigating patients with cancer [20,21]. Fig.…”

Section: The Decision Tree: a Provider-facing Resourcementioning

confidence: 99%

Using decision trees to enhance interdisciplinary team work: the case of oncofertility

Gardino

Jeruss

Woodruff

2010

J Assist Reprod Genet

View full text Add to dashboard Cite

Purpose Oncofertility, an emerging discipline at the intersection of cancer and fertility, strives to give cancer patients options when they are confronting potential infertility as a consequence of cancer treatment. Fertility preservation decisions must be made before treatment begins, adding stress to the decision-making process. Methods Healthcare providers need to be aware of the intricacies involved in oncofertility decision making, and the often tight time line that patients face when making these decisions. Cancer patient's perspectives may also change, as the dual burden of a cancer diagnosis and potential infertility can cause great flux in emotions. Results A provider-facing decision tree was created to enhance patient decision-making capacities and outline the multiple potential intervention points. Conclusions Decision trees, which highlight the important decision points during which providers can approach patients, can be a useful tool to help providers in counseling patients on fertility preservation.

show abstract

Obstetric outcomes following vitrification of in vitro and in vivo matured oocytes

Cited by 193 publications

References 49 publications

The influence of amifostine administration prior to cyclophosphamide on in vitro maturation of mouse oocytes

The influence of amifostine administration prior to cyclophosphamide on in vitro maturation of mouse oocytes

Oncofertility in Canada: cryopreservation and alternative options for future parenthood

Using decision trees to enhance interdisciplinary team work: the case of oncofertility

Contact Info

Product

Resources

About